Articles Tagged With: NIH
-
Has the Pandemic Increased the Likelihood of Bioterror?
Has the global disruption and widespread death caused by SARS-CoV-2 made biological pathogens a more compelling and/or attainable goal by bioterrorists? There are differing views on this question, although all can agree that this is the last thing healthcare workers need to deal with.
-
U.S. Long COVID Strategy Takes Flight
HHS opens Office of Long COVID Research and Practice, NIH begins enrollment for key clinical trials.
-
ID Doc: COVID-19 Can Be Controlled, Not Eradicated
Monica Gandhi, MD, MPH, is associate division chief of the HIV, Infectious Diseases, and Global Medicine at UCSF/San Francisco General Hospital. She has followed the COVID-19 pandemic closely. Hospital Employee Health sought Gandhi’s thoughts on the end of the Public Health Emergency.
-
NIH Funds Research Network on Harm Reduction
Grants will support scientists studying novel tactics to prevent opioid overdose deaths.
-
Vaccine Expert: SARS-CoV-2 Is Becoming Endemic
Make of it what you will in an unpredictable pandemic, but one of the nation’s leading vaccine and immunology experts sees COVID-19 fading to a somewhat undefined endemic level and then returning as a seasonal virus next winter. -
NIH Awards Grant for Psychedelic-Related Investigation
First federal investment in decades indicates evolving attitudes on this area of research.
-
Cost to Treat U.S. Patients with Rare Diseases Likely Underestimated
NIH, FDA, other groups form consortium to speed gene therapy development.
-
When Complaints Are Not Resolved
IRBs can resolve most research-related complaints, but a policy implemented last year by the National Institutes of Health’s Office of Human Subjects Research Protections offers assistance when the conflict reaches a stalemate. -
United Kingdom Begins First COVID-19 Human Challenge Study
Lawmakers, academics, and the research community have hotly debated the ethics of a human challenge study since the first months of the COVID-19 pandemic. Now that the United Kingdom has started dosing patients in its human challenge study, some bioethicists say this trial can show vaccine efficacy in ways the larger vaccine trials cannot.
-
AstraZeneca Reports 79% Efficacy for U.S. COVID-19 Vaccine Candidate
But NIH raises questions the about data.